is an Indian Biopharmaceutical giant based in Bangalore. Its the biggest manufacturer of fermentation products in India and has a strong foothold in Mabs and chemical synthesis products too.
It started back in 1979, nearly two and a half decades ago, with its market in India, pan-Europe and USA for selling enzymes using solid substrate fermentation. After a huge success it started climbing the success stairs with submerged fermentation and mammalian cell culture products. It has received huge recognition in the market for its large scale fermentation manufacturing capacity and for its R&D's expertise on technical patents and for development of new challenging fermentation products (like statins, antibiotics, resin based fermentation, peptides, immuomodulators etc). It has tie-ups with biggest players of the biotechnology world and has been able to deliver best and affordable products to India and world. Apart from business company indulges in philanthropic and extra-curricular activities too.
Here you can find some recent developments and company vacancies (as mentioned in their job site).
Science Magazine conducts a worldwide annual survey for companies based on Six Key parameters:
- Innovative Leader in the Industry
- Treats Employees with Respect
- Is Socially Responsible
- Has Loyal Employees
- Does Important Quality Research
- Makes Changes Needed
Biocon was ranked in 19th position leaving around 25K companies behind. And its the only Asian company in the list.
Alzumab a novel monoclonal antibody based drug for treatment of Psoriasis is all set to launch this July. Psoriasis is an auto-immune skin disease which causes inflammation with its major symptoms being redness and burning. With current survey data around 2-3% of country's population is suffering from the same. There have been chemical treatment routes which are accompanied by side effects and unsatisfactory results. A biologic route (like using an antibody) is more safe and effective to bring a relief in the patients.
Biocon the biggest manufacturer of Insulin in India is all set to enter Malaysia. It has planned to open a 40 acre facility at Bio-Xcell, Johor Malaysia. It will be a high end research and manufacturing facility to provide affordable diabetic drugs. This will create multiple opportunities for young bio-researchers of Asia.
For more news on Biocon click here.
Following are vacancies for India and Bangalore R&D center of Biocon. Kindly see the list below and apply on the company website